Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemoptysis Hemorrhage Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

VA Medical Center

Oklahoma City, Oklahoma, 73104, United States

About this study

This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Any patient scheduled to undergo bronchoscopy

Exclusion criteria

Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
Patients not scheduled to undergo bronchoalveolar lavage (BAL)

Treatment and study plan

Secondary outcomes

Volume of blood loss during the procedure

Time frame: 1 day

Sponsors and collaborators

Lead sponsor

University of Oklahoma

Other

Registry information

Official study title

Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2011
First posted: Jun 29, 2009
Registry last updated: Apr 9, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed